



Pneumococcal Vaccines Work Group

April 2025, ACIP meeting

April 15, 2025

Miwako Kobayashi

National Center for Immunization and Respiratory Diseases

Pneumococcal Vaccines Work Group

ACIP Members

- Jamie Loehr (Chair)
- Mini Kamboj
- George Kuchel
- Robert Schechter

Ex Officio Members

- Tina Mongeau (FDA)
- Nick Geagan (FDA)
- Uzo Chukwuma (IHS)
- Mamodikoe Makhene (NIH, primary)
- Meenu Upadhyay (NIH, alternate)
- Risa Claytor (HRSA)

Liaison Representatives

- Lynn Fisher (AAFP)
- Monica Ardura (AAP/COID)

- Jason Goldman (ACP)
- Saba Hasan (ACP, alternate)
- James McAuley (IDSA)
- Eva Wong (NACI)
- Robert Hopkins (NFID, primary)
- William Schaffner (NFID, alternate)
- Michelle Floris-Moore (NMA)
- Mary Hayney (APhA)

Consultants

- Monica Farley (Emory)
- Keith Klugman (Gates Foundation)
- Kathy Poehling (Wake Forest)
- Arthur Reingold (UC Berkley)
- Lorry Rubin (CCMC)
- Richard Zimmerman (U. of Pittsburgh)

CDC Contributors

Arctic Investigations Program

- Heather Scobie

CDC Lead

- Miwako Kobayashi

Division of Bacterial Diseases

- Adam Cohen
- Ryan Gierke
- Noele Nelson

Immunization Safety Office

- Pedro Moro

Immunization Services Division

- Nancy Wong

Pneumococcal Work Group Terms of Reference

- Review evidence to inform use of new pneumococcal conjugate vaccines in U.S. adults and children

History of US Pneumococcal Vaccine Program, 1984–2024


PPSV23: adults aged ≥65 years and individuals with underlying conditions

PCV13: Adults with immunocompromising conditions

PCV13: All adults aged ≥65

PCV13 based on SCDM for all adults aged ≥65 years

PCV21: Adults



PCV=pneumococcal conjugate vaccine, PPSV23=23-valent pneumococcal polysaccharide vaccine, SCDM=shared clinical decision-making

Current gaps in pneumococcal vaccine recommendations

- **Pregnant women**
 - Currently no recommendation

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection CD4 percentage and count		Men who have sex with men	Asplenia, complement deficiency	Heart or lung disease	Kidney failure, End-stage renal disease or on dialysis	Chronic liver disease; alcoholism ^a	Diabetes	Health care Personnel ^b
			<15% or <200/mm ³	≥15% and ≥200/mm ³							
Pneumococcal i											

Legend

<p>Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity</p>	<p>Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease</p>	<p>Recommended vaccination based on shared clinical decision-making</p>	<p>Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.</p>	<p>Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction</p>	<p>Contraindicated or not recommended *Vaccinate after pregnancy, if indicated</p>	<p>No Guidance/Not Applicable</p>
--	--	---	--	---	--	-----------------------------------

Current gaps in pneumococcal vaccine recommendations

- **Hematopoietic Stem Cell Transplant (HSCT) recipients**
 - Different vaccination schedule compared with other risk conditions (last updated in 2023)
 - No clinical guidance for PCV21 use

Proposed work plan

- **Review of literature on pneumococcal vaccine use in pregnant women and HSCT recipients focusing on data on:**
 - Pneumococcal disease incidence and serotype distribution
 - Vaccine efficacy, effectiveness, and impact
 - Immunogenicity
 - Safety
- **Plan to present summary of findings and proposed language for updated clinical guidance on pneumococcal vaccine use at the [June 2025 ACIP meeting](#)**

Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 [cdc.gov](https://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U. S. Centers for Disease Control and Prevention.